Cell Therapy Center, Ajou University School of Medicine, Suwon, Korea.
J Cell Physiol. 2021 Aug;236(8):5865-5874. doi: 10.1002/jcp.30270. Epub 2021 Jan 11.
Despite studies reporting functional differentiation of liver cells, a three-dimensional, vascularized liver organ has yet to be developed from mesenchymal stem cells. We investigated whether treatment with photobiomodulation (PBM) before three-dimensional liver spheroid transplantation improved the recovery of liver function via stimulation of angiogenesis and hepatocyte differentiation. Liver spheroids composed of hepatic, endothelial, and mesenchymal cells were subjected to PBM therapy. To evaluate the in vivo therapeutic effect of the liver spheroids treated with PBM, phosphate-buffered saline, liver spheroid, and PBM-treated liver spheroid were transplanted into a damaged host liver using conventional chimeric mouse models. To further characterize the maturation of transplanted PBM-liver spheroid compared with the newly generated non-PBM-liver spheroid or human liver tissues, the expression profiles of mature liver signature genes were analyzed. Liver spheroids expressed hepatocyte growth factors, including vascular endothelial growth factor and angiogenic factors. The cells in liver spheroid compensated for the low viability and improved the function of hepatocytes. Here, we demonstrate the formation of vascularized and functional human liver spheroid from human adipose-derived stem cells by transplantation of liver tissue created in vitro. Albumin secretion by PBM-treated liver spheroid was higher on Day 28 compared with liver spheroid-seeded transplant group. PBM-liver spheroids serve as individual vascularization units, promoting the simultaneous development of new microvascular networks at different locations inside the implanted tissue constructs. The vasculature in the liver spheroid transplants became functional by connecting to the host vessels within 48 h. These PBM-liver spheroids may be useful in designing artificial three-dimensional hepatic tissue constructs and in cell therapy with limited numbers of human hepatocytes.
尽管有研究报道了肝细胞的功能分化,但尚未从间充质干细胞中开发出具有三维血管化的肝器官。我们研究了在三维肝球体移植前进行光生物调节(PBM)治疗是否通过刺激血管生成和肝细胞分化来改善肝功能的恢复。由肝、内皮和间充质细胞组成的肝球体接受 PBM 治疗。为了评估经 PBM 处理的肝球体在受损宿主肝脏中的体内治疗效果,使用传统嵌合小鼠模型将磷酸盐缓冲盐水、肝球体和 PBM 处理的肝球体移植到受损的宿主肝脏中。为了进一步表征与新生成的非 PBM-肝球体或人肝组织相比,移植的 PBM-肝球体的成熟度,分析了成熟肝特征基因的表达谱。肝球体表达包括血管内皮生长因子和血管生成因子在内的肝细胞生长因子。球体中的细胞补偿了低活力并改善了肝细胞的功能。在这里,我们通过体外创建的肝组织移植,证明了从人脂肪来源干细胞形成具有血管化和功能的人肝球体。与肝球体接种移植组相比,PBM 处理的肝球体在第 28 天的白蛋白分泌更高。PBM-肝球体作为单个血管化单位,促进在植入组织构建物的不同位置同时形成新的微血管网络。肝球体移植中的血管在 48 小时内通过与宿主血管连接而变得功能化。这些 PBM-肝球体可用于设计人工三维肝组织构建物和用有限数量的人肝细胞进行细胞治疗。
Biotechnol Bioeng. 2022-2
Regen Biomater. 2022-10-12